For NCE for treament of major depressive disorder
Suven Life Sciences announced that its drug discovery portfolio has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators which resulted in the grant of one (1) product patent from USA (8653071), corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and this Patent is valid through 2030.The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With this new patent, Suven has a total of eighteen (18) granted patents from USA.
Powered by Capital Market - Live News
